Meeting
2011 ASCO Annual Meeting
Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrate resistant prostate cancer (CRPC).
Authors
H. M. Vankayala
Karmanos Cancer Institute, Wayne State University, Detroit, MI
H. M. Vankayala , L. K. Heilbrun , J. A. Fontana , U. N. Vaishampayan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Prostate Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS185)
Abstract #
TPS185
Poster Bd #
46G
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
First Author: Ignacio Gil-Bazo
Poster
2024 ASCO Genitourinary Cancers Symposium
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
First Author: Geoffrey Johnson
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2021 ASCO Annual Meeting
ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi